Until now, India, Brazil and Thailand have been among the biggest generic ARV producers, both for their own people and for export. This production has been crucial for the supply of affordable treatment in the developing world. It has resulted in competition between producers, which has reduced the price of many ARVs from as much as US$15,000/year per person for a course of combination treatment to as little as US$150/year per person. How have recent outcomes of WTO or bilateral agreements changed the situation?
Contributing Organization:
HIV Legal Network
HIV Legal Network
Contact person:
Terry Gould
Terry Gould
Publication Date:
2006
2006
Resource Type:
Area(s) of focus:
Topic(s):
Specific population(s):
Download resource(s):
Copyright:
Contact the contributor for copyright permissions.
Contact the contributor for copyright permissions.
Record last updated:
Fri, 15/08/2014 - 15:44
Fri, 15/08/2014 - 15:44